EW

— Fundamental Stock Analysis and Report Card

Healthcare : Medical - Devices

Located in Irvine, CA, US. Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Growth

Revenue, earnings and profitability.

Strong revenue growth and earnings can attract investors, driving the stock price up. Profitability indicates the company's efficiency and sustainability, which impacts investor confidence. Poor performance in these areas can lead to a decrease in stock price.

Revenue History

Earnings History

Margins

Gross Margin TTM
78.01%
EBITDA Margin TTM
22.54%
Net Margin TTM
17.34%
Earnings Per Share TTM
1.89
Statements

Income & Cash Flow analysis.

An income statement shows what a company earned and spent over a period — revenue at the top, costs and expenses in between, and net income at the bottom. A cash flow statement tracks the actual cash moving in and out, across operations, investing, and financing. Read together, they show whether reported earnings are backed by real cash.

Edwards Lifesciences Corporation
Select Period:
Q1 2026
Total ($)
Q1 2026
Margin (%)
Revenue
1.6b
+235.9m
+16.7%
Gross Income
1.3b
+178.2m
+16.0%
78%
-0.4pp
-0.6%
EBITDA
499.9m
+29.4m
+6.2%
30%
-3.0pp
-9.0%
Operating Income
514.7m
+119.9m
+30.4%
31%
+3.3pp
+11.7%
Net Income
380.7m
+22.7m
+6.3%
23%
-2.2pp
-8.9%
Earnings Per Share
0.66
+0.1
+8.2%
Operating Cash Flow
43.8m
-236.6m
-84.4%
3%
-17.2pp
-86.6%
Free Cash Flow
-21.1m
-245.5m
-109.4%
-1%
-17.2pp
-108.1%
Research & Development
263.3m
+8.7m
+3.4%
16%
-2.1pp
-11.4%